EE200000438A - Farmatseutiliselt aktiivne morfolinool - Google Patents

Farmatseutiliselt aktiivne morfolinool

Info

Publication number
EE200000438A
EE200000438A EEP200000438A EEP200000438A EE200000438A EE 200000438 A EE200000438 A EE 200000438A EE P200000438 A EEP200000438 A EE P200000438A EE P200000438 A EEP200000438 A EE P200000438A EE 200000438 A EE200000438 A EE 200000438A
Authority
EE
Estonia
Prior art keywords
pharmaceutically active
morpholinol
active morpholinol
pharmaceutically
active
Prior art date
Application number
EEP200000438A
Other languages
English (en)
Inventor
Frederick Morgan Phillip
Lee Musso David
Joseph Partridge John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000438A publication Critical patent/EE200000438A/et
Publication of EE04452B1 publication Critical patent/EE04452B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000438A 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine EE04452B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (2)

Publication Number Publication Date
EE200000438A true EE200000438A (et) 2001-12-17
EE04452B1 EE04452B1 (et) 2005-04-15

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000438A EE04452B1 (et) 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Country Status (30)

Country Link
US (2) US6274579B1 (et)
EP (2) EP1047428B1 (et)
JP (1) JP2002501025A (et)
KR (1) KR100568063B1 (et)
CN (2) CN1203858C (et)
AP (1) AP1229A (et)
AT (1) ATE365042T1 (et)
AU (1) AU755536B2 (et)
BR (1) BR9907203A (et)
CA (1) CA2318268A1 (et)
CY (1) CY1106828T1 (et)
DE (1) DE69936335T2 (et)
DK (1) DK1047428T3 (et)
EA (1) EA002410B1 (et)
EE (1) EE04452B1 (et)
ES (1) ES2288012T3 (et)
HR (2) HRP20000494B1 (et)
HU (1) HUP0100900A3 (et)
ID (1) ID26334A (et)
IL (2) IL137346A0 (et)
IS (1) IS2494B (et)
NO (2) NO326878B1 (et)
NZ (3) NZ505809A (et)
PL (1) PL193622B1 (et)
PT (1) PT1047428E (et)
SG (1) SG115489A1 (et)
SK (1) SK10912000A3 (et)
TR (1) TR200002126T2 (et)
WO (1) WO1999037305A1 (et)
YU (1) YU67102A (et)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
WO1999038503A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (en) * 2000-12-21 2008-10-21 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
JP2007509856A (ja) * 2003-10-27 2007-04-19 スミスクライン ビーチャム コーポレーション （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CA2800219C (en) 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
CA2800220C (en) 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines and analogues thereof
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
US6274579B1 (en) 2001-08-14
DE69936335T2 (de) 2008-02-28
KR20010034285A (ko) 2001-04-25
NO20003721D0 (no) 2000-07-20
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
CA2318268A1 (en) 1999-07-29
IS2494B (is) 2009-02-15
NO326878B1 (no) 2009-03-09
DK1047428T3 (da) 2007-10-08
EP1047428B1 (en) 2007-06-20
AU755536B2 (en) 2002-12-12
NZ529316A (en) 2004-05-28
NZ505809A (en) 2002-09-27
NZ520349A (en) 2004-02-27
HUP0100900A2 (hu) 2002-05-29
HRP20000494A2 (en) 2000-12-31
BR9907203A (pt) 2000-10-17
ATE365042T1 (de) 2007-07-15
JP2002501025A (ja) 2002-01-15
EE04452B1 (et) 2005-04-15
EA002410B1 (ru) 2002-04-25
SK10912000A3 (sk) 2001-04-09
WO1999037305A1 (en) 1999-07-29
EP1047428A1 (en) 2000-11-02
NO20083529L (no) 2000-09-19
PL342012A1 (en) 2001-05-07
CN1294513A (zh) 2001-05-09
HRP20000494B1 (en) 2009-02-28
KR100568063B1 (ko) 2006-04-07
US6391875B2 (en) 2002-05-21
HRP20051024A2 (hr) 2006-04-30
PL193622B1 (pl) 2007-02-28
ID26334A (id) 2000-12-14
EA200000691A1 (ru) 2001-04-23
DE69936335D1 (de) 2007-08-02
YU67102A (sh) 2004-12-31
EP1047428A4 (en) 2001-12-19
US20020019396A1 (en) 2002-02-14
IS5568A (is) 2000-07-20
ES2288012T3 (es) 2007-12-16
TR200002126T2 (tr) 2000-12-21
SG115489A1 (en) 2005-10-28
IL161942A0 (en) 2005-11-20
PT1047428E (pt) 2007-09-07
NO20003721L (no) 2000-09-19
HUP0100900A3 (en) 2002-08-28
AP2000001869A0 (en) 2000-09-30
EP1829544A1 (en) 2007-09-05
AP1229A (en) 2003-12-04
AU2328099A (en) 1999-08-09
CY1106828T1 (el) 2012-05-23
CN1255389C (zh) 2006-05-10
CN1203858C (zh) 2005-06-01

Similar Documents

Publication Publication Date Title
NO20003721D0 (no) Farmasøytisk aktivt morfolinol
PT1220856E (pt) Compostos farmaceuticamente activos
NL350038I2 (nl) Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazolinederivaten
DE69926752D1 (de) Therapeutisch wirksame biaryl-derivate
GB9823101D0 (en) Pharmaceutically active compounds
DE50007846D1 (de) Dreschkorb
DE60009395D1 (de) Bildanzeige
MA26473A1 (fr) Composes pharmacologiquement actifs.
FI20020892L (fi) Farmaseuttisesti aktiivisia isoindoliinin derivaattoja
DK1218374T3 (da) Farmaceutisk aktive sulfonamidderivater
NO992692L (no) Nefadozon doseringsform
NO993443D0 (no) Kabinstruktur
GB9823102D0 (en) Pharmaceutically active compounds
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
DE50015795D1 (de) Sektionaltor
DE59902159D1 (de) Aktiver mikromischer
FI991568A7 (fi) Farmaseuttisesti aktiivisia trisyklisiä amiineja
NO20005769L (no) Cyklosporinderivater
DE59903807D1 (de) Wirkstoffkonzentrat
EP1157700A4 (en) ANTI-HIV SUBSTANCE
SE9802539D0 (sv) New pharmaceutically active compounds
IS8740A (is) Lyfjafræðilega virkt morfólínól
SE9700660D0 (sv) Pharmaceutically active compounds
ATA203199A (de) Ablauf
SE9704874D0 (sv) New pharmaceutically active compounds

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130120